Bank employee receives six-month sentence for insider trading; Fight over Valeant investments leads two Sequoia Fund independent directors to resign; Merck buys animal vax maker;

@FiercePharma: Aratana unveils branding and partnering plans at investor day. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: whacking 1,200 jobs, closing plants in US, Ireland, Italy and Spain, but building one in Switzerland. Article | Follow @EricPFierce

@CarlyHFierce: Boehringer ups the ante in IPF drug race with awareness funding. FiercePharmaMarketing report | Follow @CarlyHFierce

> Investments in Valeant Pharmaceuticals ($VRX) led two independent directors of Sequoia Fund, Valeant's largest investor, to resign abruptly. Story

> A former Bank of New York Mellon employee who admitted making $737,000 trading on tips a friend at Merck & Co. ($MRK) supplied him about potential pharma mergers has been ordered to forfeit the profits, pay fines and spend 6 months in jail. Story

> Merck Animal Health has acquired Ames, IA-based animal vaccines maker Harrisvaccines for an undisclosed sum. Release

> With the population aging, a GBI Research report pegs the global market for prostate cancer treatments is to reach $13.6 billion by 2021 from $7.6 billion last year. Item

Medical Device News

@FierceMedDev: Resurgent 23andMe CEO says the genetic testing company is not up for sale. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage. Story | Follow @VarunSaxena2

@EmilyWFierce: Women are suing Endo Health Solutions and Patheon for child support after contraceptive packaging mishap. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Startup gets $14.3M from U.S. military to eliminate imaging in large vessel trauma procedure. Story

> GE Healthcare partners with an Oregon university for cardiovascular research. News

> Medical marijuana startup develops Keurig-like vaporizer device. Article

Biotech News

@FierceBiotech: Soon-Shiong's NantKwest is spending more on stock buybacks than R&D. Report | Follow @FierceBiotech

@JohnCFierce: Anacetrapib will be either the best come-from-behind PhIII victory or an awfully expensive new cautionary tale about R&D hubris. Hmmmm. | Follow @JohnCFierce

@DamianFierce: Tough day at the Robert J. Coury Global Center, on 1000 Mylan Blvd. More from the WSJ | Follow @DamianFierce

> Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub. Article

> Mesoblast disappoints in another below-the-range biotech IPO. Item

> AstraZeneca wins big with fast FDA OK of AZD9291 for lung cancer. News